Eli Lilly’s pursuit of outsourcing deals continues unabated with the pharma major entering into a cardiovascular R&D collaboration with Zydus Cadila that has been described as a “new paradigm for global alliances”.
Eli Lilly has agreed to acquire ImClone for $6.5bn and in doing so appears to have snatched the biotech away from Bristol-Myers Squibb (BMS), which first tabled a bid back in July.
Mere weeks after signing major strategic collaborations with contract service firms Covance, Quintiles and 3i, Eli Lilly has journeyed further down the outsourcing route – albeit with a different spin – by forging another agreement with India’s Jubilant...
The future of Eli Lilly's API manufacturing facility in Lafayette, Indiana has been thrown into doubt by the news the company is considering selling it.
Eli Lilly plans to cut 500 jobs, mainly in manufacturing, as it
attempts to restructure its operations to mitigate against the
losses from inhaled insulin.
US-based drug delivery specialist Alkermes is cutting its losses
following Eli Lilly's decision to scrap the companies' joint
development programme for inhaled insulin.
Eli Lilly has again teamed up with Indian research firm Suven Life
Sciences in a deal that will focus on preclinical research of
molecules in the therapeutic area of central nervous system (CNS)
disorders.
The prospects for a viable market in inhaled insulin therapies were
looking markedly thinner this week after Eli Lilly pulled the plug
on its joint development programme with drug delivery specialist
Alkermes for AIR Insulin.
A long-acting injectable formulation of Eli Lilly's blockbuster
schizophrenia treatment Zyprexa (olanzapine), with the potential to
improve patient adherence and take some of the sting out of generic
competition three years down...
Despite often attracting a barrage of negative publicity,
particularly in regard to a perception of putting profits before
people, big pharma firms are still capable of showing their human
side in times of crisis.
Eli Lilly has agreed to fork out $18m (€12.8m) to settle an ongoing
lawsuit with one of its former biotech research partners and in
doing so has avoided a court battle earmarked for next year.
Positive results from a Phase II trial have shown that Eli Lilly's
latest antipsychotic drug acts on a new target and avoids key
adverse effects caused by other antipsychotics.
Giant drug manufacturer Eli Lilly last week announced a reshuffle
in its global manufacturing operations to reflect the company's
focus on its current product portfolio and drug pipeline.
Eli Lilly has signed a new agreement with drug delivery specialist
Alkermes for the manufacture of its new inhaled insulin drug - AIR
- in advance of the product's market launch.
The US Food and Drug Administration (FDA) has approved Janssen's
new drug Invega (paliperidone); the first new prescription drug for
the treatment of schizophrenia since 2003.
Giant drug maker Eli Lilly has confirmed that it will be closing
its manufacturing facility in Basingstoke, England, resulting in
$85m to $95m in restructuring costs for the company.
Pharmaceutical company Eli Lilly, has been asked to justify its
decision to outsource its animal testing to countries with no or
poor animal welfare standards, which go against Lilly's commitment
to reducing, refining, and replacing...
Drug maker Eli Lilly has completed the first phase of a $560m
(€446m) expansion of its biotech facility in Indianapolis, US, in
order to match the growing number of biological drugs in its
pipeline.
Eli Lilly has splashed out $2.1bn (€1.7bn) to buy ICOS, who the
drug giant has been involved in a joint venture with to manufacture
and sell Cialis (tadalafil) - the number two erectile dysfunction
drug behind Viagra (sildenafil).
Determined to slash operational costs, Eli Lilly has decided to
shut down its pill and tablet manufacturing plant in Basingstoke
and boost production in its remaining three dry product sites.
Injectable insulin is under threat. The imminent arrival of
non-injectable insulin could finally topple the big insulin players
off their comfortable perch, in the $7 bn industry that has seen
little real competition until now.
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
US drug company, Eli Lilly, offered a more encouraging outlook than
was expected forecasting an earnings growth of up to 12 per cent, a
stark contrast to its struggling competitors, who also face generic
competition, drug safety and...
Drug major Eli Lilly has provided a detailed response to a US
congressional committee request for details of how the firm intends
to tackle the issue of drug counterfeiting.
Isis Pharmaceuticals and Eli Lilly say they have reached a mutually
beneficial renegotiation of their manufacturing relationship for
cancer drug Affinitak
US pharmaceutical major Eli Lilly has earmarked a hefty £220
million (€304 million) investment over the next four years in its
UK facilities, representing the largest investment by the firm in
any European country.